EMBC SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating Embecta Corp. (NASDAQ: EMBC) regarding potential violations of federal securities laws after the company reported second-quarter 2026 earnings that fell below analyst expectations and reduced its full-year guidance. This news led to a significant 58% drop in Embecta's share price. Investors who purchased Embecta securities are encouraged to contact the law firm to discuss their rights.
Embecta Corp. (EMBC) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky is investigating Embecta Corp. (EMBC) following a securities fraud investigation. This comes after Embecta's Q2 FY2026 revenue and EPS fell short of guidance and analyst expectations, causing the stock to drop over 25% in one session. The firm encourages investors who suffered losses to contact them to discuss their legal rights regarding potentially misleading statements made by the company.
Embecta Corp stock (US29082K1051): analyst price cut and sliding share price put diabetes specialist in focus
Embecta Corp (EMBC) is under renewed pressure after Bank of America cut its price target to $3 while maintaining a neutral stance, despite some valuation models suggesting the stock is deeply discounted. The company, which specializes in insulin-delivery devices, has seen its share price decline significantly over the past year. Embecta's business model relies on recurring revenue from consumable products for diabetes care, but it faces challenges from competitive dynamics, regulatory pressures, and evolving diabetes treatment technologies.
Embecta closes Owen Mumford acquisition for up to $201M
Embecta has finalized its acquisition of Owen Mumford Holdings for an upfront payment of 100 million pounds plus up to 50 million pounds in performance-based payments, totaling potentially $201 million. This acquisition helps Embecta, traditionally focused on diabetes care, expand into broader medical supplies and markets such as autoimmune diseases and anaphylaxis, leveraging Owen Mumford's auto-injector platform and manufacturing capabilities. The deal is expected to contribute to Embecta's revenue growth starting in its 2027 fiscal year.
Embecta closes Owen Mumford acquisition for up to $201M
Embecta has finalized its acquisition of Owen Mumford Holdings, a deal worth up to $201 million. This strategic move shifts Embecta's focus from primarily diabetes products to a broader range of medical supplies, including auto-injectors, lancets, and syringes. The acquisition is expected to help Embecta expand into new markets like autoimmune diseases and anaphylaxis and leverage Owen Mumford's device design and manufacturing capabilities.
Embecta Corp stock (US29082K1051): diabetes specialist updates investors after recent earnings
Embecta Corp, a pure-play diabetes-care company, recently updated investors with its latest quarterly figures and guidance, drawing attention from US healthcare investors. The company focuses on insulin-delivery solutions, providing reliable devices like pen needles and syringes. While facing cost pressures and competition, Embecta aims to maintain margins and gradually reduce debt through cost-control initiatives and strategic expansions.
Embecta (EMBC) price target decreased by 24.00% to 12.92
This article reports that the price target for Embecta (EMBC) has been decreased significantly by 24.00% to $12.92. This adjustment could reflect a change in analyst outlook or market conditions affecting the company.
User | poteaudailynews.com - Embecta Corp. - Common Stock (Nasdaq:EMBC) Stock Quote
This article provides a stock quote and related news for Embecta Corp. (NASDAQ: EMBC). It details the current stock price, trading volume, bid/ask prices, range, dividend yield, and recent performance, showing a significant year-to-date decline. Additionally, it lists recent news headlines concerning Embecta's quarterly reports, business strategies, and stock performance.
Embecta Completes Owen Mumford Acquisition to Expand Devices
Embecta Corporation (EMBC) has completed its acquisition of Owen Mumford Holdings Limited for £100 million in upfront cash, with a potential additional £50 million based on commercial milestones. This acquisition aims to accelerate Embecta's expansion into a comprehensive medical supplies company, broadening its chronic care device offerings and enhancing its drug delivery platforms for pharmaceutical clients and patients with conditions like obesity and diabetes. Despite this strategic move, TipRanks' AI Analyst, Spark, maintains a Neutral outlook on EMBC due to financial stress and bearish technicals, tempered by recent cash generation and diversification efforts.
embecta Completes Acquisition of Owen Mumford Holdings Limited
Embecta Corp. has completed its acquisition of Owen Mumford Holdings Limited for an upfront cash payment of £100 million and potential performance-based payments of up to £50 million. This acquisition accelerates embecta's transformation into a broad-based medical supplies company, expanding its drug delivery platforms for pharmaceutical companies and chronic care patients in various therapeutic areas. The deal combines Owen Mumford's device design and manufacturing expertise with embecta's global commercial infrastructure and large-scale manufacturing capabilities.
embecta Completes Acquisition of Owen Mumford Holdings Limited
Embecta Corp. (embecta), a leader in diabetes care technology, has completed its acquisition of Owen Mumford Holdings Limited. This acquisition, for an upfront cash payment of £100 million and potential performance-based payments of up to £50 million, aims to accelerate embecta's transformation into a broad-based medical supplies company, expanding its drug delivery platforms and chronic care device portfolio. The deal leverages Owen Mumford's device design expertise with embecta's global infrastructure to enhance market reach and operational efficiency.
Press Release: Embecta Completes Acquisition of Owen Mumford Holdings Limited
Embecta Corp. announced the successful completion of its acquisition of Owen Mumford Holdings Limited. This strategic acquisition is expected to accelerate Embecta's growth, expand its product portfolio into new areas, and enhance its R&D capabilities. The integration will bring together two companies focused on improving the lives of people with diabetes and other chronic conditions.
Embecta completes acquisition of Owen Mumford to expand drug delivery and chronic care device offerings.
Embecta Corp. has finalized its acquisition of Owen Mumford Holdings Limited for an initial £100 million plus up to £50 million in performance-based payments. This acquisition aims to transform Embecta into a broad-based medical supplies company by integrating Owen Mumford's drug delivery platforms and chronic care devices. The strategic move is expected to expand Embecta's geographic reach and operational efficiencies, enabling better service to pharmaceutical partners and chronic care patients.
Embecta (Nasdaq: EMBC) closes up to £150M Owen Mumford deal
Embecta (Nasdaq: EMBC) has finalized its acquisition of UK-based medical device maker Owen Mumford Holdings Limited for an upfront cash payment of £100 million, with a potential additional £50 million tied to commercial milestones of the Aidaptus® auto-injector platform. This strategic move aims to broaden Embecta's focus beyond insulin delivery into a wider array of medical supplies and drug-delivery platforms, covering areas like obesity, diabetes, and autoimmune diseases. The acquisition integrates Owen Mumford's device design and manufacturing capabilities with Embecta's global commercial network.
Diabetes tech firm embecta buys UK auto-injector maker for £100M
Embecta (Nasdaq: EMBC) has completed its acquisition of Owen Mumford Holdings, a UK-based medical device and drug delivery innovator, for an upfront cash payment of £100 million and potential performance-based payments of up to £50 million. This acquisition aims to broaden embecta's presence in medical supplies and drug delivery platforms, expanding its chronic care product portfolio across various therapeutic areas. The deal provides embecta with a differentiated drug-delivery platform and strengthens its manufacturing and commercial capabilities globally.
embecta Completes Acquisition of Owen Mumford Holdings Limited
embecta has completed its acquisition of Owen Mumford Holdings Limited for an upfront cash payment of £100 million and potential performance-based payments of up to an additional £50 million. This acquisition is set to accelerate embecta's transformation into a broad-based medical supplies company, enhancing its drug delivery platform capabilities and expanding its market reach in chronic care. The deal combines Owen Mumford's device design and manufacturing with embecta's global presence and manufacturing expertise.
embecta Completes Acquisition of Owen Mumford Holdings Limited
Embecta Corp. (Nasdaq: EMBC), a global leader in diabetes care technology, has finalized its acquisition of Owen Mumford Holdings Limited, a UK-based innovator in medical devices and drug delivery. The transaction, involving an upfront cash payment of £100 million and potential performance-based payments up to an additional £50 million, accelerates embecta's transformation into a broad-based medical supplies company. The acquisition brings Owen Mumford's differentiated drug-delivery platforms, including the Aidaptus® next-generation auto-injector, and its chronic care device portfolio, enhancing embecta's capabilities in serving various therapeutic areas.
Embecta Corp stock (US29082K1051): Shares slide after conference update
Embecta Corp's shares garnered attention after a conference presentation on May 13, 2026, with the stock trading near its 52-week low. The company, a small-cap healthcare stock focusing on diabetes care devices, sees its investment case tied to recurring demand, margin execution, and a high dividend yield of 17.6%. Investors are watching for improved operating performance and diversification strategies to mitigate current pressures and cautious market sentiment.
Levi & Korsinsky Announces Investigation of Securities Claims Against Embecta Corp. (EMBC)
Levi & Korsinsky, LLP has announced an investigation into potential securities law violations by Embecta Corp. (EMBC) after its shares dropped over 25%. This decline followed a Q2 FY2026 earnings miss and a reduction in full-year guidance, despite previous assurances from management that results were "exceeding expectations." The law firm is encouraging shareholders who suffered losses to come forward and discuss their legal rights.
EMBC Investor Alert: Levi & Korsinsky Investigates Embecta Corp. (EMBC) for Potential Securities Fraud
Levi & Korsinsky is investigating Embecta Corp. (EMBC) for potential securities fraud after the company slashed its full-year FY2026 financial outlook, causing shares to drop over 25%. This reversal followed earlier reaffirmations of guidance, which had initially projected revenues between $1.071 and $1.093 billion. Shareholders who experienced losses are encouraged to contact the firm for a free evaluation of their potential claims.
Transcript : Embecta Corp. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03
This article provides a transcript of Embecta Corp.'s presentation at the Bank of America Global Healthcare Conference 2026. The presentation, featuring CEO and President Dev Kurdikar, took place on May 13, 2026. The full transcript content is reserved for subscribers.
EMBC Investor Alert: Levi & Korsinsky Investigates Embecta Corp. (EMBC) for Potential Securities Fraud
Levi & Korsinsky, LLP is investigating Embecta Corp. (EMBC) for potential securities fraud after its shares fell over 25%. This investigation follows Embecta's decision to cut its full-year FY2026 financial outlook, which it had previously reaffirmed. The firm encourages investors who suffered losses to contact them for an evaluation.
Embecta stock rating held at Neutral by BTIG after investor meetings By Investing.com
BTIG has reiterated its Neutral rating on Embecta (NASDAQ:EMBC) following recent virtual investor meetings. The decision comes after the stock plunged 61% in the past week due to weak Q2 fiscal 2026 earnings and a guidance cut. Investors are seeking clarity on how the company plans to address U.S. market weaknesses and rebuild credibility, while management aims to transform Embecta into a broad-based medical supplies company, starting with stabilizing its core U.S. business.
Number of shareholders of Embecta Corp. – NASDAQ:EMBC
This article focuses on the number of shareholders for Embecta Corp. (NASDAQ: EMBC). It presents a table with period, value, change, and percentage change data related to its shareholders. The content is primarily a data placeholder within a financial platform interface.
Investors can hear embecta management at BofA conference on May 13
Embecta (Nasdaq: EMBC) will present at the 2026 BofA Securities Global Health Care Conference on May 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. The announcement comes after a period of significant company developments, including weak Q2 2026 results, a dividend cut, and the strategic acquisition of Owen Mumford. Investors will likely focus on management's plan for growth, margin recovery, and balance sheet priorities during the presentation.
embecta to Participate at the 2026 BofA Securities Global Health Care Conference
Embecta Corp. (embecta) will present at the 2026 BofA Securities Global Health Care Conference on Wednesday, May 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. An audio webcast of the presentation will be available on the company's investor relations website. Embecta is a global company focused on medical supplies, building on its legacy in insulin delivery.
Embecta Corp. (EMBC) Stock Analysis: A High Dividend Yield and Potential Upside of 122.22%
Embecta Corp. (EMBC) offers investors a high dividend yield of 12.74% and a potential upside of 122.22% based on analyst targets, despite declining revenue and cautious market sentiment. The company, which specializes in diabetes solutions, currently trades at $3.60, with technical indicators suggesting it is oversold. Investors should weigh the attractive yield against revenue challenges and consider a longer-term investment horizon.
Embecta Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EMBC) 2026-05-07
Embecta Corp. (EMBC) has released its Q2 2026 earnings call presentation. The company reported an EPS of $0.27, missing estimates by $0.15, and revenue of $221.80 million, a 14.36% year-over-year decrease, missing estimates by $13.86 million. This presentation details the financial results and related insights for the quarter.
Embecta: A Sharp Decline On Q2 Earnings, But There's Still No Opportunity (NASDAQ:EMBC)
Embecta (EMBC) experienced a sharp decline in Q2 earnings with revenue falling 14% and U.S. revenues plunging 29%. The company also slashed its dividend significantly and carries a high debt load, making its financial situation increasingly precarious. Despite a buyback program, the author does not see this as a buying opportunity given the accelerating revenue declines and overall challenging outlook.
Embecta Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Embecta Corp. (NASDAQ: EMBC) following a sharp decline in stock price. This decline occurred after Embecta reported disappointing Q2 fiscal 2026 financial results, including significant revenue decreases and reduced full-year guidance for revenue, operating margin, and EPS, along with a reduced quarterly dividend. The investigation focuses on whether Embecta's executive officers complied with federal securities laws given these disclosures, which were primarily driven by U.S. business pressures and competitive share loss.
Investigation Launched into Embecta Corp. by Johnson Fistel
Johnson Fistel has initiated an investigation into Embecta Corp. (EMBC) to determine if the company violated federal securities laws, prompted by a significant decline in financial performance, a reduced full-year outlook, and a substantial dividend cut. Embecta reported a 14.4% year-over-year revenue decline in Q2 fiscal 2026 and lowered its revenue guidance for the year, while also cutting its quarterly dividend from $0.15 to $0.01 per share. Investors who experienced losses due to these financial setbacks may have legal recourse.
Embecta Corp. (NASDAQ:EMBC) Q2 2026 Earnings Call Transcript
Embecta Corp. (NASDAQ: EMBC) reported a challenging Q2 2026 with revenues down 14.4% year-over-year, leading to a significant reduction in its full-year guidance. The decline was primarily attributed to share loss in the U.S. pen needle market and overall market volume softness for insulin pens, potentially influenced by increased GLP-1 drug affordability and the expiration of ACA subsidies. Despite these setbacks, Embecta is pursuing a strategic transformation by diversifying into a broader medical supplies company, anchored by the impending acquisition of Owen Mumford and expansion of its B2B GLP-1 strategy, while also approving a share repurchase program and reducing its quarterly dividend to enhance financial flexibility.
Mizuho cuts Embecta stock price target on weak US sales performance
Mizuho has significantly lowered its price target for Embecta Corp. (NASDAQ:EMBC) to $5.00 from $12.00, while maintaining a Neutral rating, citing weak US sales performance in the second fiscal quarter. The company missed revenue expectations by $14 million, primarily due to competitive pressures, market softness for insulin pens, and pen-needle share loss within the US. This led to a substantial cut in Embecta's fiscal 2026 revenue and adjusted earnings per share guidance, with analysts expecting continued headwinds from low-cost providers and GLP-1 drugs.
Embecta Corp reports results for the quarter ended March 31 - Earnings Summary
Embecta Corp has released its earnings summary for the quarter that concluded on March 31. The report, provided by Refinitiv, gives an overview of the company's financial performance. Further details would typically be found within the full earnings report.
embecta Announces Quarterly Cash Dividend
Embecta Corp. (EMBC) has declared a quarterly cash dividend of $0.01 per share of its common stock. The dividend is scheduled to be paid on June 15, 2026, to stockholders of record as of May 28, 2026. Embecta is a global medical supplies company focused on insulin delivery and innovative solutions.
Yacktman Asset Mgmt, AMG Yacktman Fund Report Stakes in Embecta (EMBC)
Yacktman Asset Management LP and AMG Yacktman Fund have reported significant passive institutional holdings in Embecta Corp. (EMBC) through a Schedule 13G filing. Yacktman Asset Management LP holds 6.20% of the common stock, while AMG Yacktman Fund holds 5.07%, both indicating shared voting and dispositive powers. The filing, dated May 5, 2026, details these stakes and clarifies that the Adviser maintains investment and voting power over the securities for its clients.
Embecta forecasts $1.015B-$1.035B FY 2026 revenue while launching $100M buyback and cutting dividend to $0.01
Embecta (EMBC) is projecting revenues of $1.015 billion to $1.035 billion for fiscal year 2026. This announcement comes alongside the initiation of a $100 million share repurchase program and a significant reduction in its quarterly dividend to just $0.01 per share.
Embecta (NASDAQ: EMBC) revenue drops as debt, buyback and Owen Mumford deal reshape 2026
Embecta Corp. (EMBC) reported a Q2 2026 revenue drop of 14.4% to $221.8 million and a net loss of $4.1 million, largely due to lower volumes and pricing pressure in pen needles and U.S. markets. Despite maintaining high debt of $1.34 billion, the company engaged in strategic financial maneuvers including a $75.0 million term loan prepayment, approval of a $100.0 million share repurchase program, and a significant dividend cut from $0.15 to $0.01 per share. Additionally, Embecta entered an agreement to acquire UK-based Owen Mumford for up to £150 million, aiming to expand into drug-delivery technologies.
Embecta Corp. announces an Equity Buyback for $100 million worth of its shares.
Embecta Corp. has announced a share repurchase program, authorizing the buyback of up to $100 million worth of its common stock. This program will be valid for a period of three years. The news was published on May 5, 2026, by S&P Capital IQ.
Embecta Q2 2026 Earnings Call Transcript
Embecta reported a difficult fiscal Q2 2026, with revenue declining 14.4% year-over-year and a significant cut to full-year guidance due to share loss in pen needles and overall market volume softness in the U.S. The company is actively addressing these challenges through cost-structure review, strategic initiatives, and the acquisition of Owen Mumford, which is expected to diversify its portfolio and contribute to future revenue growth. Embecta also revised its capital allocation, authorizing a $100 million share repurchase program and reducing its quarterly dividend to support debt reduction and strategic flexibility.
Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results
Embecta Corp. (Nasdaq: EMBC) announced its second quarter fiscal 2026 financial results. The company, focused on advancing its legacy in insulin delivery towards becoming a broad-based medical supplies company, has made the detailed earnings release and investor presentation available on its investor relations website. A conference call and webcast were held on May 5, 2026, for analysts and investors to discuss the results.
Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results
Embecta Corp. (Nasdaq: EMBC) announced its second quarter fiscal 2026 financial results, which are available on the company's Investor Relations website. The company also hosted a conference call and webcast for analysts and investors to discuss these results. Embecta aims to leverage its legacy in insulin delivery to become a broader medical supplies company.
Guidance cut, buyback and dividend reduction at Embecta (Nasdaq: EMBC)
Embecta (EMBC) reported significantly weaker-than-expected Q2 fiscal 2026 results, with revenue down 14.4% and a net loss of $4.1 million. The company slashed its full-year 2026 guidance, citing U.S. market headwinds, but simultaneously announced a three-year, $100 million share repurchase program and reduced its quarterly dividend from $0.15 to $0.01 per share to reallocate capital towards buybacks and debt reduction. Management still plans to repay approximately $150 million in debt in 2026 and expects the Owen Mumford acquisition to close in May 2026, adding revenue but diluting EPS.
Embecta declares $0.01 quarterly dividend payable June 15 By Investing.com
Embecta Corp. (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.01 per share, which will be paid on June 15, 2026, to shareholders of record as of May 28, 2026. This dividend represents an annual yield of 6.49%, and InvestingPro tips highlight Embecta for its significant dividend payments. The company recently reported strong fiscal first-quarter 2026 earnings, surpassing analyst expectations, and announced the acquisition of Owen Mumford Holdings Limited.
embecta Announces Quarterly Cash Dividend
Embecta Corp. (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 per share of its common stock. This dividend is scheduled to be paid on June 15, 2026, to shareholders who are on record as of May 28, 2026. Embecta is recognized as a global medical supplies company, building on its 100-year history in insulin delivery.
embecta shareholders on record by May 28 get June 15 payout
Embecta (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 per share, payable on June 15, 2026, to shareholders of record as of May 28, 2026. This announcement led to a significant negative market reaction, with EMBC stock declining 24.32% shortly after the news, reducing the company's valuation by approximately $176 million. Despite the dividend, the nominal payout is considered immaterial for many investors.
embecta Announces Quarterly Cash Dividend
Embecta Corp. (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 per share. This dividend is payable on June 15, 2026, to stockholders recorded by May 28, 2026. Embecta is a global medical supplies company known for its legacy in insulin delivery.
Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results
Embecta Corp. (Nasdaq: EMBC) announced its second-quarter fiscal 2026 financial results. The company, which is expanding its focus from insulin delivery to broad-based medical supplies, will host a conference call and live webcast for analysts and investors to discuss the results. Detailed financial information and the investor presentation are available on Embecta's Investor Relations website.
Embecta (Nasdaq:EMBC) - Stock Analysis
Embecta (Nasdaq:EMBC) is a medical device company focused on diabetes solutions. The stock is currently trading significantly below its estimated fair value, but faces risks including negative shareholder equity and declining earnings forecasts. Recent news indicates a share buyback program and analysts have adjusted price targets, reflecting a more cautious stance despite the company's efforts towards M&A and margin improvements.
EMBC - Embecta Corp Stock Price and Quote
This page provides a detailed financial overview of Embecta Corp (EMBC), including its stock price, key financial metrics, recent news, analyst ratings, and insider transactions. The data reveals current trading information, performance indicators, and a historical timeline of company news and analyst actions.
